Illuminate®

Book a briefing

Every

Every

discovery deserves

discovery deserves

a clearer path to patients.

a clearer path to patients.

Regulatory strategy,

clinical technology,

and

market access

under one roof,

built for approvals and outcomes rather than slide decks.

Book a briefing

Explore our work

  • FDA

  • EMA

  • MHRA

  • PMDA

  • Swissmedic

  • Health Canada

  • TGA

  • ANVISA

  • FDA

  • EMA

  • MHRA

  • PMDA

  • Swissmedic

  • Health Canada

  • TGA

  • ANVISA

Every engagement begins with one honest question.

No pitch decks, no junior hand-offs. Before we propose anything, a partner sits with your team, finds the decision that matters most — and builds the evidence around it.

How we work

Scientific consultants discussing evidence in a bright clinical research office

Where is our evidence weakest?

Your Phase II endpoints won’t satisfy European HTA bodies. That’s a launch problem, not a trial problem.

Can we fix it without delaying the readout?

Yes. Add one validated secondary endpoint and pre-register the analysis. Let’s start there.

  • Hypotheses become protocols

  • Protocols become evidence

  • Evidence becomes approval

  • Approval becomes access

  • Access becomes outcomes

  • Hypotheses become protocols

  • Protocols become evidence

  • Evidence becomes approval

  • Approval becomes access

  • Access becomes outcomes

White medical research atrium

– In medicine, clarity is not a style. It is a safety standard.

Dr. Helena Voss, Managing Partner

White medical research atrium

– In medicine, clarity is not a style. It is a safety standard.

Dr. Helena Voss, Managing Partner

White medical research atrium

– In medicine, clarity is not a style. It is a safety standard.

Dr. Helena Voss, Managing Partner

Six disciplines. One standard of evidence.

All services

Six disciplines. One standard of evidence.

All services

Service practice photo

Regulatory Strategy

Service practice photo

Clinical Development

Service practice photo

AI & Digital Health

Service practice photo

Market Access & HEOR

Service practice photo

Manufacturing & CMC

Service practice photo

Scientific Due Diligence

Where science, regulation and markets finally meet.

Meet the partners

Where science, regulation and markets finally meet.

Meet the partners

Sterile manufacturing in the White Architecture photographic series

Scientific depth

Partners with MD, PhD and PharmD backgrounds who read the data themselves — not through a slide deck.

Scientific depth

Partners with MD, PhD and PharmD backgrounds who read the data themselves — not through a slide deck.

Regulatory fluency

Former agency reviewers and notified-body assessors who know how decisions are actually made.

Regulatory fluency

Former agency reviewers and notified-body assessors who know how decisions are actually made.

Technology & AI

Data scientists and engineers who validate algorithms, models and digital endpoints to clinical standard.

Technology & AI

Data scientists and engineers who validate algorithms, models and digital endpoints to clinical standard.

Wherever evidence decides, we are in the room.

Wherever evidence decides, we are in the room.

Precision microscopy in the White Architecture photographic seriesSterile manufacturing in the White Architecture photographic seriesWhite MRI suite in the White Architecture photographic seriesMedical research atrium in the White Architecture photographic seriesMicropipette and microplate in the White Architecture photographic seriesDiagnostic expert in the White Architecture photographic series

Turning insight into structured execution.

Start with a briefing

Turning insight into structured execution.

Start with a briefing

Precision microscopy in the White Architecture photographic series

01

Diagnose

We interrogate the data, the plan and the people to find the one decision that changes the outcome.

Precision microscopy in the White Architecture photographic series

01

Diagnose

We interrogate the data, the plan and the people to find the one decision that changes the outcome.

Clinical protocol planning in the White Architecture photographic series

02

Design

Options are modelled against evidence, cost and time — then stress-tested with expert panels.

Clinical protocol planning in the White Architecture photographic series

02

Design

Options are modelled against evidence, cost and time — then stress-tested with expert panels.

Research evidence review in the White Architecture photographic series

03

Deliver

Partners stay hands-on through submissions, agency meetings and board reviews.

Research evidence review in the White Architecture photographic series

03

Deliver

Partners stay hands-on through submissions, agency meetings and board reviews.

Remote patient monitoring in the White Architecture photographic series

04

Sustain

Clear milestones, monthly read-outs and a team that remains on call as the science evolves.

Remote patient monitoring in the White Architecture photographic series

04

Sustain

Clear milestones, monthly read-outs and a team that remains on call as the science evolves.

0+

Agency interactions prepared

$0bn

Transactions advised on

0%

Programmes delivered on time

0+

Specialists in our expert network

Clear pharmaceutical glass vials

– We remove everything that is not evidence. What remains is the decision.

Prof. Julian Ashworth, Senior Partner

Clear pharmaceutical glass vials

– We remove everything that is not evidence. What remains is the decision.

Prof. Julian Ashworth, Senior Partner

Clear pharmaceutical glass vials

– We remove everything that is not evidence. What remains is the decision.

Prof. Julian Ashworth, Senior Partner

Outcomes our clients can publish.

All case studies

Outcomes our clients can publish.

All case studies

−12 mo

Twelve months back on an oncology timeline

9 mo

AI ECG clearance in nine months

3 sites

Biologics scale-up across three sites

−31%

Readmissions down by a third

Why not simply hire a larger firm?

Typical approach

Generalist teams rotated across industries

Slide-heavy reports, weeks after the decision

Junior analysts do most of the work

Advice independent of regulators’ reality

Hourly billing with open-ended scope

Illuminate

Clinicians, scientists and ex-regulators only

Decision memos timed to your governance calendar

Partners stay hands-on from first call to filing

Mock panels with former agency reviewers

Fixed fees against defined deliverables

What leadership teams tell us afterwards.

What leadership teams tell us afterwards.

  • The rare advisor who is equally comfortable in front of an agency panel and inside a data room. Every recommendation came with the evidence behind it.

    The rare advisor who is equally comfortable in front of an agency panel and inside a data room. Every recommendation came with the evidence behind it.

    Client portrait

    Dr. Lena Brandt

  • They spoke fluent machine learning and fluent FDA. Our clearance came months earlier than our own plan assumed.

    They spoke fluent machine learning and fluent FDA. Our clearance came months earlier than our own plan assumed.

    Client portrait

    Tomas Riedel

  • Calm, precise and unusually honest. They told us what we needed to hear, not what we wanted to hear — and that saved the programme.

    Calm, precise and unusually honest. They told us what we needed to hear, not what we wanted to hear — and that saved the programme.

    Client portrait

    Priya Raman

  • For the first time our digital programme was evaluated with the same rigour as a new drug. The board noticed.

    For the first time our digital programme was evaluated with the same rigour as a new drug. The board noticed.

    Client portrait

    Dr. Ana Kovač

  • Their investment memo was the one document our committee actually read cover to cover.

    Their investment memo was the one document our committee actually read cover to cover.

    Client portrait

    Olivia Hart

Notes for sharper scientific decisions.

All insights

Notes for sharper scientific decisions.

All insights

The EU AI Act meets the MDR: a field guide for 2027

Adaptive trials are finally going mainstream

Real-world evidence that payers actually trust

Questions? We’re glad you asked.

Dr. Helena Voss

Dr. Helena Voss

Still deciding? A 20-minute call with a partner usually settles it.

Schedule a call

How does an engagement usually start?

Do you work with early-stage companies?

How are your fees structured?

Who will actually do the work?

Which therapeutic areas do you cover?

Can you represent us in agency meetings?

Create a free website with Framer, the website builder loved by startups, designers and agencies.